<DOC>
	<DOCNO>NCT01525888</DOCNO>
	<brief_summary>The aim current study evaluate prospectively whether concomitant administration renin-angiotensin-aldosterone system ( RAAS ) blocker ( namely ACE-I ARBs ' ) influence change estimate glomerular filtration rate GFR ( eGFR ) administration contrast medium patient undergo non-emergent coronary angiography .</brief_summary>
	<brief_title>Renin-angiotensin-aldosterone System ( RAAS ) Blockade Contrast Induced Nephropathy</brief_title>
	<detailed_description>Contrast-induced nephropathy ( CIN ) define absolute relative increase serum creatinine compare baseline value , together exposure contrast agent exclusion alternative explanation renal impairment . Most frequently renal impairment develop 48 hour post exposure . Although RAAS block agent widely use among patient require contrast study , data regard effect agent development CIN sparse inconsistent . Patients undergo percutaneous coronary intervention frequently treat RAAS block agent . Despite infrequent occurrence CIN follow percutaneous coronary intervention ( PCI ) guideline available topic cessation RAAS inhibitor prior procedure .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>age &gt; 18 year , chronic therapy ACEI and/or ARBs ' ( confirm electronic record medical file ) plan coronary angiography chronic utilization NSAIDS Cox2 selective inhibitor , chronic treatment mineralocorticosteroid receptor blocker , administration contrast within 14 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Contrast induce nephropathy</keyword>
</DOC>